Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Upregulation of Osteoactivin Upon Exposure to Tyrosine Kinase Inhibitors Impairs the T Cell Stimulatory Capacity of Monocyte-Derived Dendritic Cells

Michael Gutknecht, Lisa Güttler, Mark-Alexander Schwarzbich, MD, Julia Salih, Lothar Kanz, MD, Helmut R. Salih, MD, Susanne Malaika Rittig, MD, Frank Grünebach, PD

Blood (2011) 118 (21): 1112.

https://doi.org/10.1182/blood.V118.21.1112.1112

Published: 2011

Journal Articles

The Immune-Inhibitory Receptor Osteoactivin Is up-Regulated In Monocyte-Derived Dendritic Cells Upon Exposure to Tyrosine Kinase Inhibitors

Michael Gutknecht, Mark-Alexander Schwarzbich, Julia Salih, Lothar Kanz, MD, Helmut R. Salih, MD, Susanne M. Schmidt, Frank Grünebach

Blood (2010) 116 (21): 1733.

https://doi.org/10.1182/blood.V116.21.1733.1733

Published: 2010

Journal Articles

BCR/ABL Inhibitors Influence Phenotype and Function of Monocyte-Derived Human Dendritic Cells.

Susanne M. Schmidt, Christian J. Lechner, Frank Gruenebach, Julia Salih, Lothar Kanz, Hans-Georg Rammensee, Helmut R. Salih

Blood (2009) 114 (22): 1116.

https://doi.org/10.1182/blood.V114.22.1116.1116

Published: 2009

Journal Articles

The Role of the PI3K-AKT-mTOR Pathway in NK Cell Anti-Tumor Reactivity.

Matthias Krusch, MD, Julia Salih, Ingrid Kumbier, Carolin Fenner, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2009) 114 (22): 3690.

https://doi.org/10.1182/blood.V114.22.3690.3690

Published: 2009

Journal Articles

The FLT3-Inhibitors Midostaurin, Sunitinib, Sorafenib, and TKI258 Differentially Affect NK Cell-Mediated Immunesurveillance of Acute Myeloid Leukemia.

Julia Salih, Lothar Kanz, MD, Helmut R Salih, MD, Matthias Krusch, MD

Blood (2009) 114 (22): 3785.

https://doi.org/10.1182/blood.V114.22.3785.3785

Published: 2009

Journal Articles

Differential Effects of the BCR-ABL-Inhibitors Imatinib, Nilotinib and Dasatinib on NK Cell Reactivity against Chronic Myeloid Leukemia (CML)

Matthias Krusch, MD, Julia Salih, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2008) 112 (11): 3200.

https://doi.org/10.1182/blood.V112.11.3200.3200

Published: 2008

Journal Articles

NK Cell Anti-Tumor Immune Responses Are Impaired by Sorafenib but Not by Sunitinib

Matthias Krusch, MD, Manuela Schlicke, Julia Salih, Tina Baessler, Lothar Kanz, MD, Helmut Salih, MD

Blood (2008) 112 (11): 2632.

https://doi.org/10.1182/blood.V112.11.2632.2632

Published: 2008

NARROW

Upregulation of Osteoactivin Upon Exposure to Tyrosine Kinase Inhibitors Impairs the T Cell Stimulatory Capacity of Monocyte-Derived Dendritic Cells

The Immune-Inhibitory Receptor Osteoactivin Is up-Regulated In Monocyte-Derived Dendritic Cells Upon Exposure to Tyrosine Kinase Inhibitors

BCR/ABL Inhibitors Influence Phenotype and Function of Monocyte-Derived Human Dendritic Cells.

The Role of the PI3K-AKT-mTOR Pathway in NK Cell Anti-Tumor Reactivity.

The FLT3-Inhibitors Midostaurin, Sunitinib, Sorafenib, and TKI258 Differentially Affect NK Cell-Mediated Immunesurveillance of Acute Myeloid Leukemia.

Differential Effects of the BCR-ABL-Inhibitors Imatinib, Nilotinib and Dasatinib on NK Cell Reactivity against Chronic Myeloid Leukemia (CML)

NK Cell Anti-Tumor Immune Responses Are Impaired by Sorafenib but Not by Sunitinib

Email alerts

ASH Publications

American Society of Hematology

Upregulation of Osteoactivin Upon Exposure to Tyrosine Kinase Inhibitors Impairs the T Cell Stimulatory Capacity of Monocyte-Derived Dendritic Cells

The Immune-Inhibitory Receptor Osteoactivin Is up-Regulated In Monocyte-Derived Dendritic Cells Upon Exposure to Tyrosine Kinase Inhibitors

BCR/ABL Inhibitors Influence Phenotype and Function of Monocyte-Derived Human Dendritic Cells.

The Role of the PI3K-AKT-mTOR Pathway in NK Cell Anti-Tumor Reactivity.

The FLT3-Inhibitors Midostaurin, Sunitinib, Sorafenib, and TKI258 Differentially Affect NK Cell-Mediated Immunesurveillance of Acute Myeloid Leukemia.

Differential Effects of the BCR-ABL-Inhibitors Imatinib, Nilotinib and Dasatinib on NK Cell Reactivity against Chronic Myeloid Leukemia (CML)

NK Cell Anti-Tumor Immune Responses Are Impaired by Sorafenib but Not by Sunitinib

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only